An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis

Bertrand Boisson, Chenhui Wang, Vincent Pedergnana, Ling Wu, Sophie Cypowyj, Michel Rybojad, Abdelaziz Belkadi, Capucine Picard, Laurent Abel, Claire Fieschi, Anne Puel, Xiaoxia Li, Jean Laurent Casanova

Research output: Contribution to journalArticle

123 Citations (Scopus)

Abstract

Patients with inborn errors of interleukin-17F (IL-17F) or IL-17RA display chronic mucocutaneous candidiasis (CMC). We report a biallelic missense mutation (T536I) in the adaptor molecule ACT1 in two siblings with CMC. The mutation, located in the SEFIR domain, abolished the homotypic interaction of ACT1 with IL-17 receptors, with no effect on homodimerization. The patients' fibroblasts failed to respond to IL-17A and IL-17F, and their Tcells to IL-17E. By contrast, healthy individuals homozygous for the common variant D10N, located in the ACT1 tumor necrosis factor receptor-associated factor-interacting domain and previously associated with psoriasis, had impaired, but not abolished, responses to IL-17 cytokines. SEFIR-independent interactions of ACT1 with other proteins, such as CD40, heat shock protein 70 (HSP70) and HSP90, were not affected by the T536I mutation. Overall, human IL-17A and IL-17F depend on ACT1 to mediate protective mucocutaneous immunity. Moreover, other ACT1-dependent IL-17 cytokines seem to be largely redundant in host defense.

Original languageEnglish
Pages (from-to)676-686
Number of pages11
JournalImmunity
Volume39
Issue number4
DOIs
Publication statusPublished - 17 Oct 2013
Externally publishedYes

Fingerprint

Chronic Mucocutaneous Candidiasis
Interleukin-17
Mutation
Interleukin-17 Receptors
Tumor Necrosis Factor Receptor-Associated Peptides and Proteins
Cytokines
HSP70 Heat-Shock Proteins
Missense Mutation
Psoriasis
Siblings
Immunity
Fibroblasts

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases
  • Immunology

Cite this

Boisson, B., Wang, C., Pedergnana, V., Wu, L., Cypowyj, S., Rybojad, M., ... Casanova, J. L. (2013). An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis. Immunity, 39(4), 676-686. https://doi.org/10.1016/j.immuni.2013.09.002

An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis. / Boisson, Bertrand; Wang, Chenhui; Pedergnana, Vincent; Wu, Ling; Cypowyj, Sophie; Rybojad, Michel; Belkadi, Abdelaziz; Picard, Capucine; Abel, Laurent; Fieschi, Claire; Puel, Anne; Li, Xiaoxia; Casanova, Jean Laurent.

In: Immunity, Vol. 39, No. 4, 17.10.2013, p. 676-686.

Research output: Contribution to journalArticle

Boisson, B, Wang, C, Pedergnana, V, Wu, L, Cypowyj, S, Rybojad, M, Belkadi, A, Picard, C, Abel, L, Fieschi, C, Puel, A, Li, X & Casanova, JL 2013, 'An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis', Immunity, vol. 39, no. 4, pp. 676-686. https://doi.org/10.1016/j.immuni.2013.09.002
Boisson, Bertrand ; Wang, Chenhui ; Pedergnana, Vincent ; Wu, Ling ; Cypowyj, Sophie ; Rybojad, Michel ; Belkadi, Abdelaziz ; Picard, Capucine ; Abel, Laurent ; Fieschi, Claire ; Puel, Anne ; Li, Xiaoxia ; Casanova, Jean Laurent. / An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis. In: Immunity. 2013 ; Vol. 39, No. 4. pp. 676-686.
@article{c61576fc32e14c20a23a59c03d124107,
title = "An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis",
abstract = "Patients with inborn errors of interleukin-17F (IL-17F) or IL-17RA display chronic mucocutaneous candidiasis (CMC). We report a biallelic missense mutation (T536I) in the adaptor molecule ACT1 in two siblings with CMC. The mutation, located in the SEFIR domain, abolished the homotypic interaction of ACT1 with IL-17 receptors, with no effect on homodimerization. The patients' fibroblasts failed to respond to IL-17A and IL-17F, and their Tcells to IL-17E. By contrast, healthy individuals homozygous for the common variant D10N, located in the ACT1 tumor necrosis factor receptor-associated factor-interacting domain and previously associated with psoriasis, had impaired, but not abolished, responses to IL-17 cytokines. SEFIR-independent interactions of ACT1 with other proteins, such as CD40, heat shock protein 70 (HSP70) and HSP90, were not affected by the T536I mutation. Overall, human IL-17A and IL-17F depend on ACT1 to mediate protective mucocutaneous immunity. Moreover, other ACT1-dependent IL-17 cytokines seem to be largely redundant in host defense.",
author = "Bertrand Boisson and Chenhui Wang and Vincent Pedergnana and Ling Wu and Sophie Cypowyj and Michel Rybojad and Abdelaziz Belkadi and Capucine Picard and Laurent Abel and Claire Fieschi and Anne Puel and Xiaoxia Li and Casanova, {Jean Laurent}",
year = "2013",
month = "10",
day = "17",
doi = "10.1016/j.immuni.2013.09.002",
language = "English",
volume = "39",
pages = "676--686",
journal = "Immunity",
issn = "1074-7613",
publisher = "Cell Press",
number = "4",

}

TY - JOUR

T1 - An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis

AU - Boisson, Bertrand

AU - Wang, Chenhui

AU - Pedergnana, Vincent

AU - Wu, Ling

AU - Cypowyj, Sophie

AU - Rybojad, Michel

AU - Belkadi, Abdelaziz

AU - Picard, Capucine

AU - Abel, Laurent

AU - Fieschi, Claire

AU - Puel, Anne

AU - Li, Xiaoxia

AU - Casanova, Jean Laurent

PY - 2013/10/17

Y1 - 2013/10/17

N2 - Patients with inborn errors of interleukin-17F (IL-17F) or IL-17RA display chronic mucocutaneous candidiasis (CMC). We report a biallelic missense mutation (T536I) in the adaptor molecule ACT1 in two siblings with CMC. The mutation, located in the SEFIR domain, abolished the homotypic interaction of ACT1 with IL-17 receptors, with no effect on homodimerization. The patients' fibroblasts failed to respond to IL-17A and IL-17F, and their Tcells to IL-17E. By contrast, healthy individuals homozygous for the common variant D10N, located in the ACT1 tumor necrosis factor receptor-associated factor-interacting domain and previously associated with psoriasis, had impaired, but not abolished, responses to IL-17 cytokines. SEFIR-independent interactions of ACT1 with other proteins, such as CD40, heat shock protein 70 (HSP70) and HSP90, were not affected by the T536I mutation. Overall, human IL-17A and IL-17F depend on ACT1 to mediate protective mucocutaneous immunity. Moreover, other ACT1-dependent IL-17 cytokines seem to be largely redundant in host defense.

AB - Patients with inborn errors of interleukin-17F (IL-17F) or IL-17RA display chronic mucocutaneous candidiasis (CMC). We report a biallelic missense mutation (T536I) in the adaptor molecule ACT1 in two siblings with CMC. The mutation, located in the SEFIR domain, abolished the homotypic interaction of ACT1 with IL-17 receptors, with no effect on homodimerization. The patients' fibroblasts failed to respond to IL-17A and IL-17F, and their Tcells to IL-17E. By contrast, healthy individuals homozygous for the common variant D10N, located in the ACT1 tumor necrosis factor receptor-associated factor-interacting domain and previously associated with psoriasis, had impaired, but not abolished, responses to IL-17 cytokines. SEFIR-independent interactions of ACT1 with other proteins, such as CD40, heat shock protein 70 (HSP70) and HSP90, were not affected by the T536I mutation. Overall, human IL-17A and IL-17F depend on ACT1 to mediate protective mucocutaneous immunity. Moreover, other ACT1-dependent IL-17 cytokines seem to be largely redundant in host defense.

UR - http://www.scopus.com/inward/record.url?scp=84885865938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885865938&partnerID=8YFLogxK

U2 - 10.1016/j.immuni.2013.09.002

DO - 10.1016/j.immuni.2013.09.002

M3 - Article

C2 - 24120361

AN - SCOPUS:84885865938

VL - 39

SP - 676

EP - 686

JO - Immunity

JF - Immunity

SN - 1074-7613

IS - 4

ER -